TCRXHIGH SIGNALFINANCIAL10-K

TCRX shows severe financial deterioration with stockholders' equity collapsing 49% alongside dramatically worsening cash burn, despite a strategic pivot to focus solely on lead candidate TSC-101.

The company appears to be in significant financial distress with equity nearly halved and operating cash flow deteriorating by 22% to -$135M, indicating accelerating cash burn that threatens viability. The strategic shift from a broad TCR platform approach to focusing exclusively on TSC-101 for blood cancers suggests management is narrowing focus amid resource constraints, but this pivot comes as financial metrics are collapsing across the board.

Comparing 2026-03-04 vs 2025-03-05View on EDGAR →
FINANCIAL ANALYSIS

TCRX's financial position has deteriorated dramatically with stockholders' equity plummeting 49% to $123M and total assets shrinking 38% to $229M, while operating cash flow worsened 22% to -$135M despite revenue growing to $10M. The company's cash position declined 15% to $152M while current liabilities decreased 48%, suggesting significant balance sheet restructuring amid financial stress. The combination of massive equity destruction, worsening cash burn, and overall asset base contraction signals a company in severe financial distress that may struggle to fund operations without immediate capital infusion.

FINANCIAL STATEMENT CHANGES
Revenue
P&L
+266.7%
$2.8M$10.3M

Strong top-line growth of 266.7% — accelerating demand or successful expansion into new markets.

Stockholders Equity
Balance Sheet
-48.9%
$241.0M$123.1M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Current Liabilities
Balance Sheet
-48%
$36.0M$18.7M

Current liabilities reduced — improved short-term financial position and working capital health.

Current Assets
Balance Sheet
-46.3%
$292.7M$157.2M

Current assets declined 46.3% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-38.4%
$371.1M$228.8M

Total assets contracted 38.4% — asset sales, write-downs, or balance sheet optimization underway.

Interest Expense
P&L
-24.2%
$3.7M$2.8M

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Operating Cash Flow
Cash Flow
-22.1%
-$110.8M-$135.3M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

Total Liabilities
Balance Sheet
-18.8%
$130.1M$105.7M

Liabilities reduced 18.8% — deleveraging improves balance sheet strength and financial flexibility.

Cash & Equivalents
Balance Sheet
-14.7%
$178.7M$152.4M

Cash decreased 14.7% — monitor burn rate and upcoming capital needs.

LANGUAGE CHANGES
NEW — 2026-03-04
PRIOR — 2025-03-05
ADDED
Management's Discussion and Analysis of Financial Condition and Results of Operations 100 Item 7A.
policy, changes in governmental agencies, changes in international trade relationships and conflicts on any of the foregoing or other aspects of our business or operations including our ability to obtain additional financing; and our anticipated use of our existing cash resources and our ability to obtain additional financing in the future.
Congress and the Trump administration have made and may make substantial changes to fiscal, tax, and other federal policies that may adversely affect our business.
Our lead product candidate, TSC-101, is in development for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who are undergoing allogeneic hematopoietic cell transplantation (HCT).
The product is designed to eliminate residual disease and promote complete donor chimerism, thereby preventing relapse.
+7 more — sign up free →
REMOVED
Management's Discussion and Analysis of Financial Condition and Results of Operations 110 Item 7A.
policy, changes in international trade relationships and conflicts, such as the ongoing conflict between Russia and Ukraine, on any of the foregoing or other aspects of our business or operations including our ability to obtain additional financing; and our anticipated use of our existing cash resources and our ability to obtain additional financing in the future.
Congress or the Trump administration, may make substantial changes to fiscal, tax, and other federal policies that may adversely affect our business.
Our approach is based on the central premise that we can learn from patients who are winning their fight against cancer to treat those who are not.
Over the past several years, we have built our ImmunoBank, a repository of therapeutic TCRs that recognize diverse targets and are associated with multiple human leukocyte antigen, or HLA, types.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →